OCS 株価分析 — Oculis Holding AG Ordinary Shares (Healthcare >> Biotechnology)
OCS に関するよくある質問
OCSのROE(自己資本利益率)は?
Oculis Holding AG Ordinary SharesのROEは-48.49%です。
OCSの配当利回りは?
Oculis Holding AG Ordinary Sharesの配当利回りは0.00%です。
OCSの品質スコア(Quality Score)は?
当社のAIはOCSの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
OCSは今が買い時ですか?
当社AIのタイミングスコアは100点中28点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
OCSはどのセクターに属しますか?
Oculis Holding AG Ordinary SharesはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
OCS AI Analysis Summary
Our AI summary for OCS: Oculis Holding AG Ordinary Shares (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -48.49%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 11.99
Price
0.10
(0.84%)
Day Change
|
|
|---|
OCS, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 86 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 11.99 |
| PBV / Sector |
3.66 / 44,022.72
|
| Earning Per Share | -1.59 |
| PE / Sector |
N/A / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
3.83 M
GREAT
|
| Average 1W Daily Value |
3.36 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:00:38 |
| Symbol | OCS |
| Name | OCULIS HOLDING AG ORDINARY SHARES |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 60.39 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 718.01 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Bahnhofstrasse 20, Zug, Switzerland, 6300
Phone: 41 41 711 3960
Website: https://oculis.com
Employees: 60
Sector: Healthcare >> Biotechnology
Description: Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google